复方苦参注射液治疗乳腺癌术后化疗患者的临床疗效及其对外周血T细胞亚群的影响研究

目的:探讨复方苦参注射液治疗乳腺癌术后化疗患者的临床疗效及其对外周血T细胞亚群的影响。方法:将80例术后乳腺癌患者按照治疗方式随机分为对照组(n=37)与观察组(n=43),对照组单纯采用化疗治疗,观察组在此基础上联合复方苦参注射液治疗。比较2组临床缓解率、治疗前后免疫功能指标水平、治疗前后生存质量评分、治疗前后血象指标及细胞因子水平、治疗前后外周T细胞亚群水平。结果:(1)对照组临床缓解率(RR)为45.95%,显著低于观察组(74.42%)(P< 0.05);(2)对照组治疗后免疫功能指标(IgG、IgA、IgM)水平均显著低于治疗前(P< 0.05),但观察组治疗后上述指标水平均显著高于治疗前及对照组治疗后(P< 0.05);(3)2组治疗后Karnofsky功能状态评分标准(KPS)评分均显著高于治疗前(P< 0.05),且观察组治疗后KPS评分显著高于对照组治疗后(P< 0.05);(4)观察组治疗后WBC、PLT及IL-2水平均显著高于对照组治疗后(P< 0.05),观察组治疗后IL-6水平显著低于对照组治疗后(P< 0.05);(5)观察组治疗后外周血T细胞亚群(CD4⁺、CD8⁺及CD69)水平均显著高于治疗前及对照组治疗后(P< 0.05)。结论:复方苦参注射液治疗乳腺癌术后化疗患者的临床疗效显著,可提高外周血T细胞亚群(CD4⁺、CD8⁺及CD69)水平,应将此方法加以推广、使用。

Researches on clinical efficacy of postoperative Fufangkushen chemotherapy in patients with breast cancer and its effects on peripheral blood T cell subsets

OBJECTIVE To investigate clinical efficacy of postoperative Fufangkushen chemotherapy in patients with breast cancer and its effects on peripheral blood T cell subsets.METHODS A total of 80 patients with breast cancer were randomly divided into control group (n=37) and observation group (n=43) by different therapeutic methods.Patients in control group were treated by using chemotherapy only,while patients in observation group were given Fufangkushen injection based on chemotherapy.Clinical response rate,level of immune parameters,quality of life,blood indicators and cytokine levels,peripheral T cell subsets were compared before and after therapy.RESULTS Clinical response rate (RR) of control group was 45.95%,significantly lower than that of observation group (74.42%) (P< 0.05).After therapy,immune parameters (IgG,IgA,IgM) were significantly decreased in control group (P< 0.05) but significantly increased in observation group.These parameters after therapy in observation group were significantly higher than those in control group (P< 0.05).KPS scores were significantly increased after therapy in both group (P< 0.05),and higher in observation group than in control group (P< 0.05).After therapy,observation group had significantly higher WBC,PLT and IL-2 levels (P< 0.05),but lower IL-6 level (P< 0.05) than in control group.Peripheral blood T cell subsets (CD4⁺,CD8⁺ and CD69) after therapy were significantly higher than those before therapy,and those in control group after therapy (P< 0.05).CONCLUSION Fufangkushen injection has significant clinical efficacy in patients with breast cancer during postoperative chemotherapy,can significantly improve peripheral blood T cell subsets (CD4⁺,CD8⁺ and CD69).